News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB Group (UCBJF.PK) and Immunomedics, Inc. (IMMU) Release: Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint


11/8/2011 11:02:49 AM

BRUSSELS, Belgium, and CHICAGO, Nov. 8, 2011 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels:UCB) and U.S. based partner Immunomedics Inc. (Nasdaq:IMMU) today announced data, at the 75th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Chicago, that supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of systemic lupus erythematosus (SLE) disease activity.4

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES